Status: Recruiting
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD
This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter an 8-week Follow-up Period.
Participants needed: 300
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Transcend TherapeuticsUpdated: Sep 23, 2026Locations: 2
Eligibility criteria
Meets DSM-5 criteria for current PTSD diagnosis, with a symptom duration of at l... [+3]
Primary diagnosis of any other DSM-5 disorder. [+4]